Home
COLL
COLL News

Latest Collegium Pharmaceutical Inc. (COLL) News on March 29, 2025

Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine’s Annual Meeting

GlobeNewswire

2 days ago

Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine’s Annual Meeting

Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

GlobeNewswire

3 days ago

Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

Argus Research

4 days ago

COLL: Raising target price to $32.00

Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks

StockStory

8 days ago

Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks

Teva Pharmaceutical Stock Scores RS Rating Upgrade

Investor's Business Daily

11 days ago

Teva Pharmaceutical Stock Scores RS Rating Upgrade

Collegium Announces Updates to its Board of Directors and Executive Leadership Team

GlobeNewswire

12 days ago

Collegium Announces Updates to its Board of Directors and Executive Leadership Team

MT Newswires

16 days ago

Collegium Pharmaceutical Insider Sold Shares Worth $313,413, According to a Recent SEC Filing

Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care

GlobeNewswire

19 days ago

Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care

Collegium Pharmaceutical's (NASDAQ:COLL) Solid Earnings Are Supported By Other Strong Factors

Simply Wall St.

23 days ago

Collegium Pharmaceutical's (NASDAQ:COLL) Solid Earnings Are Supported By Other Strong Factors

Argus Research

25 days ago

COLL: Lowering target price to $29.00

Collegium to Participate in Upcoming Investor Conferences

GlobeNewswire

25 days ago

Collegium to Participate in Upcoming Investor Conferences

Collegium Pharmaceutical Full Year 2024 Earnings: In Line With Expectations

Simply Wall St.

a month ago

Collegium Pharmaceutical Full Year 2024 Earnings: In Line With Expectations

Should You Be Adding Collegium Pharmaceutical (NASDAQ:COLL) To Your Watchlist Today?

Simply Wall St.

a month ago

Should You Be Adding Collegium Pharmaceutical (NASDAQ:COLL) To Your Watchlist Today?

Is Collegium Pharmaceutical, Inc. (COLL) the Best Small Cap Pharma Stocks to Buy Now?

Insider Monkey

a month ago

Is Collegium Pharmaceutical, Inc. (COLL) the Best Small Cap Pharma Stocks to Buy Now?

Thomson Reuters StreetEvents

a month ago

Q4 2024 Collegium Pharmaceutical Inc Earnings Call

GuruFocus.com

a month ago

Collegium Pharmaceutical Inc (COLL) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...

Collegium Pharmaceutical (COLL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks

a month ago

Collegium Pharmaceutical (COLL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Beat Estimates

Zacks

a month ago

Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Beat Estimates

Associated Press Finance

a month ago

Collegium Pharmaceutical: Q4 Earnings Snapshot

Collegium Pharmaceutical’s (NASDAQ:COLL) Q4 Sales Top Estimates, Stock Jumps 14.1%

StockStory

a month ago

Collegium Pharmaceutical’s (NASDAQ:COLL) Q4 Sales Top Estimates, Stock Jumps 14.1%

Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results

GlobeNewswire

a month ago

Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results

Seeking Clues to Collegium Pharmaceutical (COLL) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

Zacks

a month ago

Seeking Clues to Collegium Pharmaceutical (COLL) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect

StockStory

a month ago

Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect

GuruFocus.com

a month ago

What To Expect From Collegium Pharmaceutical Inc (COLL) Q4 2024 Earnings

Argus Research

a month ago

COLL: Lowering target price to $30.00

Argus Research

a month ago

COLL: Lowering target price to $31.00

Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

GlobeNewswire

a month ago

Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

Collegium Appoints Nancy S. Lurker to its Board of Directors

GlobeNewswire

2 months ago

Collegium Appoints Nancy S. Lurker to its Board of Directors

Argus Research

2 months ago

COLL: Lowering target price to $32.00

Argus Research

2 months ago

COLL: Lowering target price to $34.00

Argus Research

2 months ago

COLL: What does Argus have to say about COLL?

MT Newswires

2 months ago

Collegium Pharmaceutical Insider Sold Shares Worth $908,628, According to a Recent SEC Filing

MT Newswires

3 months ago

Needham Upgrades Collegium Pharmaceutical to Buy From Hold, Price Target is $46

Collegium Pharmaceutical Unveils 2025 Financial Projections

TipRanks

3 months ago

Collegium Pharmaceutical Unveils 2025 Financial Projections

MT Newswires

3 months ago

Collegium Pharmaceutical Shares Rise After 2025 Guidance

Collegium Provides 2025 Financial Guidance and Business Update

GlobeNewswire

3 months ago

Collegium Provides 2025 Financial Guidance and Business Update

Pulling back 6.0% this week, Collegium Pharmaceutical's NASDAQ:COLL) three-year decline in earnings may be coming into investors focus

Simply Wall St.

3 months ago

Pulling back 6.0% this week, Collegium Pharmaceutical's NASDAQ:COLL) three-year decline in earnings may be coming into investors focus

Argus Research

3 months ago

COLL: Lowering target price to $31.00

Argus Research

3 months ago

COLL: What does Argus have to say about COLL?

Argus Research

4 months ago

COLL: What does Argus have to say about COLL?

Argus Research

4 months ago

COLL: Lowering target price to $32.00

Argus Research

4 months ago

COLL: Raising target price to $33.00

Collegium Pharmaceutical's (NASDAQ:COLL) Performance Is Even Better Than Its Earnings Suggest

Simply Wall St.

4 months ago

Collegium Pharmaceutical's (NASDAQ:COLL) Performance Is Even Better Than Its Earnings Suggest

Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?

Zacks

5 months ago

Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?

Argus Research

5 months ago

COLL: Lowering target price to $33.00

Collegium to Participate in Upcoming Investor Conferences

GlobeNewswire

5 months ago

Collegium to Participate in Upcoming Investor Conferences

Collegium Pharmaceutical Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

5 months ago

Collegium Pharmaceutical Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

GuruFocus.com

5 months ago

Collegium Pharmaceutical Inc (COLL) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...

Is the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock?

Zacks

5 months ago

Is the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock?

Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings

Zacks

5 months ago

Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings

Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Lag Estimates

Zacks

5 months ago

Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Lag Estimates

Associated Press Finance

5 months ago

Collegium Pharmaceutical: Q3 Earnings Snapshot

Collegium Reports Record Third Quarter 2024 Financial Results

GlobeNewswire

5 months ago

Collegium Reports Record Third Quarter 2024 Financial Results

Collegium Appoints Vikram Karnani as Chief Executive Officer

GlobeNewswire

5 months ago

Collegium Appoints Vikram Karnani as Chief Executive Officer

What To Expect From Collegium Pharmaceutical Inc (COLL) Q3 2024 Earnings

GuruFocus.com

5 months ago

What To Expect From Collegium Pharmaceutical Inc (COLL) Q3 2024 Earnings

Argus Research

5 months ago

COLL: Lowering target price to $35.00

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks

5 months ago

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Collegium Pharmaceutical to Report Q3 Earnings: What's in the Cards?

Zacks

5 months ago

Collegium Pharmaceutical to Report Q3 Earnings: What's in the Cards?

Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?

Zacks

5 months ago

Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?

Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024

GlobeNewswire

5 months ago

Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024

Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?

Zacks

6 months ago

Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?

GuruFocus.com

6 months ago

Collegium Pharmaceutical Inc (COLL) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Argus Research

6 months ago

COLL: Lowering target price to $40.00

Breakouts Boost These Three Stocks To All-Time Highs

Investor's Business Daily

6 months ago

Breakouts Boost These Three Stocks To All-Time Highs

Should We Be Delighted With Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) ROE Of 46%?

Simply Wall St.

6 months ago

Should We Be Delighted With Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) ROE Of 46%?

Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now?

Zacks

6 months ago

Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now?

Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?

Zacks

7 months ago

Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?

Collegium Pharmaceutical (COLL) Upgraded to Buy: Here's Why

Zacks

7 months ago

Collegium Pharmaceutical (COLL) Upgraded to Buy: Here's Why

Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?

Zacks

7 months ago

Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?

Insider Sale: EVP and General Counsel Shirley Kuhlmann Sells 20,225 Shares of Collegium ...

GuruFocus.com

7 months ago

Insider Sale: EVP and General Counsel Shirley Kuhlmann Sells 20,225 Shares of Collegium ...

MT Newswires

7 months ago

Collegium Pharmaceutical Insider Sold Shares Worth $773,792, According to a Recent SEC Filing

MT Newswires

7 months ago

Collegium Closes Acquisition of Ironshore Therapeutics; Boosts 2024 Product Revenue

Collegium Completes Acquisition of Ironshore Therapeutics

GlobeNewswire

7 months ago

Collegium Completes Acquisition of Ironshore Therapeutics

Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire

7 months ago

Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Collegium Announces Eight Poster Presentations at PAINWeek Conference 2024

GlobeNewswire

7 months ago

Collegium Announces Eight Poster Presentations at PAINWeek Conference 2024

Argus Research

7 months ago

COLL: Raising target price to $40.00

Argus Research

7 months ago

COLL: Raising target price to $38.00

Shareholders Will Be Pleased With The Quality of Collegium Pharmaceutical's (NASDAQ:COLL) Earnings

Simply Wall St.

7 months ago

Shareholders Will Be Pleased With The Quality of Collegium Pharmaceutical's (NASDAQ:COLL) Earnings

Collegium Pharmaceutical (COLL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks

8 months ago

Collegium Pharmaceutical (COLL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates

Zacks

8 months ago

Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates

Associated Press Finance

8 months ago

Collegium Pharmaceutical: Q2 Earnings Snapshot

Collegium Reports Second Quarter 2024 Financial Results

GlobeNewswire

8 months ago

Collegium Reports Second Quarter 2024 Financial Results

Unveiling Collegium Pharmaceutical (COLL) Q2 Outlook: Wall Street Estimates for Key Metrics

Zacks

8 months ago

Unveiling Collegium Pharmaceutical (COLL) Q2 Outlook: Wall Street Estimates for Key Metrics

Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

8 months ago

Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?

Zacks

8 months ago

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?

Collegium Pharmaceutical (COLL) Soars 10.6%: Is Further Upside Left in the Stock?

Zacks

8 months ago

Collegium Pharmaceutical (COLL) Soars 10.6%: Is Further Upside Left in the Stock?

Collegium buys Ironshore for $525m and enter ADHD market

Pharmaceutical Technology

8 months ago

Collegium buys Ironshore for $525m and enter ADHD market

MT Newswires

8 months ago

Collegium Pharmaceutical to Acquire Ironshore Therapeutics for $525 Million

Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology

GlobeNewswire

8 months ago

Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology

Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024

GlobeNewswire

8 months ago

Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024

Argus Research

8 months ago

COLL: Raising target price to $35.00

Argus Research

8 months ago

COLL: Raising target price to $34.00

Argus Research

9 months ago

COLL: Lowering target price to $33.00

Collegium Pharmaceutical (NASDAQ:COLL) shareholders have earned a 19% CAGR over the last five years

Simply Wall St.

9 months ago

Collegium Pharmaceutical (NASDAQ:COLL) shareholders have earned a 19% CAGR over the last five years

MT Newswires

10 months ago

Collegium Pharmaceutical Says Nucynta Gets FDA Pediatric Exclusivity

Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise

GlobeNewswire

10 months ago

Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Upgraded by Jefferies

Insider Monkey

10 months ago

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Upgraded by Jefferies

Investing.com

10 months ago

Street calls of the week: Upgrades for Best Buy and Lululemon

Insider Sale: EVP and General Counsel Shirley Kuhlmann Sells 25,000 Shares of Collegium ...

GuruFocus.com

10 months ago

Insider Sale: EVP and General Counsel Shirley Kuhlmann Sells 25,000 Shares of Collegium ...

MT Newswires

10 months ago

Collegium Pharmaceutical Insider Sold Shares Worth $814,180, According to a Recent SEC Filing

Share on Social Networks: